6 results on '"Whorwell, Peter"'
Search Results
2. Quality of life and illness costs in irritable bowel syndrome.
- Author
-
Simrén M, Brazier J, Coremans G, Dapoigny M, Müller-Lissner SA, Pace F, Smout AJ, Stockbrügger RW, Vatn MH, and Whorwell PJ
- Subjects
- Clinical Trials as Topic, Endpoint Determination, Humans, Irritable Bowel Syndrome therapy, Health Care Costs statistics & numerical data, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome economics, Quality of Life, Surveys and Questionnaires
- Abstract
Quality of life is reduced in patients with irritable bowel syndrome, and the costs for this disease are substantial to society. During a meeting in London, UK, the IBiS club reviewed the literature on these subjects. Drawbacks and advantages with existing instruments to assess quality of life and costs were discussed and the clinical and scientific relevance of the current knowledge was assessed. A summary from the meeting is presented in this paper.
- Published
- 2004
- Full Text
- View/download PDF
3. The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study.
- Author
-
Jaafari, Hussain, Houghton, Lesley A., West, Robert M., Agrawal, Anurag, Aziz, Imran, Black, Christopher J., Corsetti, Maura, Shuweihdi, Farag, Eugenicos, Maria, Paine, Peter A., Ford, Alexander C., Whorwell, Peter J., Bangdiwala, Shrikant I., Palsson, Olafur S., Sperber, Ami D., and Vasant, Dipesh H.
- Subjects
GINGER ,IRRITABLE colon ,FECAL incontinence ,FOOD habits - Abstract
Background: There are minimal epidemiological data comparing the burden of disorders of gut brain interaction (DGBI) in the UK with other countries. We compared the prevalence of DGBI in the UK with other countries that participated in the Rome Foundation Global Epidemiology Study (RFGES) online. Methods: Participants from 26 countries completed the RFGES survey online including the Rome IV diagnostic questionnaire and an in‐depth supplemental questionnaire with questions about dietary habits. UK sociodemographic and prevalence data were compared with the other 25 countries pooled together. Key Results: The proportion of participants with at least one DGBI was lower in UK participants compared with in the other 25 countries (37.6% 95% CI 35.5%–39.7% vs. 41.2%; 95% CI 40.8%–41.6%, p = 0.001). The UK prevalence of 14 of 22 Rome IV DGBI, including irritable bowel syndrome (4.3%) and functional dyspepsia (6.8%), was similar to the other countries. Fecal incontinence, opioid‐induced constipation, chronic nausea and vomiting, and cannabinoid hyperemesis (p < 0.05) were more prevalent in the UK. Cyclic vomiting, functional constipation, unspecified functional bowel disorder, and proctalgia fugax (p < 0.05) were more prevalent in the other 25 countries. Diet in the UK population consisted of higher consumption of meat and milk (p < 0.001), and lower consumption of rice, fruit, eggs, tofu, pasta, vegetables/legumes, and fish (p < 0.001). Conclusions and Inferences: The prevalence and burden of DGBI is consistently high in the UK and in the rest of the world. Opioid prescribing, cultural, dietary, and lifestyle factors may contribute to differences in the prevalence of some DGBI between the UK and other countries. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The Intestinal Gas Questionnaire (IGQ): Psychometric validation of a new instrument for measuring gas‐related symptoms and their impact on daily life among general population and irritable bowel syndrome.
- Author
-
Duracinsky, Martin, Archbold, Sharon, Lobo, Beatriz, Bessonneau, Pascal, Thonon, Frédérique, Santos, Javier, Guagnozzi, Danila, Payakachat, Nalin, Coffin, Benoit, Azpiroz, Fernando, Whorwell, Peter J., and Chassany, Olivier
- Subjects
IRRITABLE colon ,MEASURING instruments ,EVERYDAY life ,FACTOR analysis ,INTRACLASS correlation ,ELECTRONIC paper - Abstract
Background: Gas‐related symptoms (GRS) are common in the general population (GPop) and among patients with disorders of gut‐brain interactions but there is no patient‐reported outcome evaluating these symptoms and their impact on daily life. We have previously developed a 43‐item intestinal gas questionnaire (IGQ). The aim of the present study is to perform a psychometric validation of this instrument. Methods: Participants (119 from the GPop and 186 irritable bowel syndrome (IBS) patients) were recruited from 3 countries (UK, Spain, France). IBS patients fulfilled ROME IV criteria with an IBS severity score between 150 and 300. Participants completed the IGQ, the functional Digestive Disorders Quality of Life (FDDQL), and the EQ‐5D. A subgroup (n = 90) repeated the IGQ completion after 7 days on paper or electronically. Results: From the original IGQ questionnaire, 26 items were deleted because of poor performance. Confirmatory factorial analysis on the remaining 17 items (7 symptom and 10 impact items) yielded a 6‐factor structure accounting for 67% of the variance for bloating (6 items), flatulence (3), belching (2), bad breath (2), stomach rumbling (2), and difficult gas evacuation (2). Global score (0‐100) was worse among IBS vs GPop (40 ± 15 vs 33 ± 17; p = 0.0016). At the second visit, the intraclass correlation coefficient of IGQ scores was between 0.71 and 0.86 (n = 67) for test‐retest reliability and 0.61‐0.87 (n = 64) for equivalence between electronic and paper versions of IGQ. Conclusion: The IGQ available in paper and electronic versions in 3 languages is a robust instrument for capturing and measuring GRS and their impact on daily life. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. SKYPE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: Effectiveness and Comparison with Face-to-Face Treatment.
- Author
-
Hasan, Shariq S., Pearson, James S., morris, Julie, and Whorwell, Peter J.
- Subjects
IRRITABLE colon treatment ,ANALYSIS of covariance ,ANXIETY ,CONFIDENCE intervals ,MENTAL depression ,HYPNOTISM ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH funding ,T-test (Statistics) ,LOGISTIC regression analysis ,TREATMENT effectiveness ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Gut-focused hypnotherapy is an effective treatment for irritable bowel syndrome but is not widely available. This study assessed whether providing hypnotherapy by Skype might partially overcome this problem. Using a 50-point or more reduction in the IBS Symptom Severity Score as the primary outcome measure, 65% of subjects responded to Skype hypnotherapy with all other outcomes significantly improving. The primary outcome figure for face-to-face hypnotherapy was 76%. When other outcome scores for Skype and face-to-face treatment were compared, the mean changes were these: symptom severity (−94.1 vs. −129.2), noncolonic score (−52.3 vs. −64.8), quality of life (+56.4 vs. +66.2), anxiety (−3.3 vs. −3.0), depression (−1.7 vs. −2.5), and a 30% or more pain reduction (44% vs. 62%). Skype hypnotherapy is effective but slightly less so than face-to-face treatment. However, many patients would have been unable to access treatment without the Skype option. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Acupuncture for irritable bowel syndrome: Aprotocol for a pragmatic randomised controlledtrial.
- Author
-
MacPherson, Hugh, Bland, Martin, Bloor, Karen, Cox, Helen, Geddes, David, Kang'ombe, Arthur, Reynolds, Julie, Stamuli, Eugena, Stuardi, Tracey, Tilbrook, Helen, Torgerson, David, and Whorwell, Peter
- Subjects
ACUPUNCTURE ,IRRITABLE colon ,RANDOMIZED controlled trials ,QUALITY of life ,MEDICAL care ,ACUPUNCTURISTS - Abstract
Background: There is insufficient evidence on the effectiveness of acupuncture for irritable bowel syndrome (IBS) for conclusions to be drawn. Given the current interest in acupuncture by patients, it is in the public interest to establish more rigorous evidence. Building on the positive findings from a pilot study, in this paper we present the protocol for a fully-powered trial designed to establish whether or not acupuncture is effective and cost-effective. Methods/Design: In this pragmatic randomised controlled trial we will randomise patients recruited directly from GP databases to either 10 sessions of acupuncture plus usual GP care or to usual GP care alone. The primary clinical outcome will be the IBS Symptom Severity Score (SSS) (maximum score 500) at three months, and at 12 month assessing whether there is an overall benefit. We estimate the sample size required to detect a minimum clinical difference at 90% power and 5% significance to be 188 patients. To allow for loss to follow up we will recruit 220 patients drawn from an estimated primary care population of 140 000. Analysis will be by intention-to-treat, and multiple imputation is to be used for missing data. In a nested qualitative study using in-depth interviews, we will explore how patients, acupuncturists, and GPs explain and subsequently understand acupuncture to work. We will use purposive sampling to identify patients and flexible topic guides for the interviews. The data analysis will lead to a thematic description of how patients and practitioners explain how acupuncture works, and whether or not the explanations influence treatment outcome and/or referrals. We will undertake a cost-effectiveness analysis at 12 months by comparing resource use in the two groups with any treatment benefit. We will use the EQ-5D to measure health-related quality of life and convert into quality adjusted life years (QALYs). We will generate cost effectiveness acceptability curves (CEACs) exploring the probability that acupuncture will produce an acceptable cost per QALY at different cost-effectiveness thresholds. Discussion: The trial has received NHS ethics approval and recruited 233 patients between November 2008 and June 2009. Results are expected in 2011. Trial Registration: Current Controlled Trials ISRCTN08827905 [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.